Researchers have identified a potential new treatment target in aggressive small cell cancers that have long resisted effective therapies. The study found that tumors missing the RB gene become highly dependent on a protein called E2F3 to survive. When researchers blocked E2F3 in laboratory models, tumor growth stopped, revealing a critical weakness that cancer cells rely on. Encouragingly, some existing FDA-approved drugs may already be able to target this pathway, potentially speeding up the development of new treatments. While more research and clinical trials are needed, this discovery offers fresh hope for improving outcomes in patients with these difficult-to-treat cancers.
Read more at ScienceDaily